GE Says Phase III Results for Flutemetamol Demonstrate Ability to Detect Beta Amyloid

Loading...
Loading...
GE Healthcare today announced pooled results from phase III brain autopsy and biopsy studies on the investigational PET amyloid imaging agent, [^18F]flutemetamol, which showed a strong concordance between [^18F]flutemetamol images and Alzheimer's disease-associated beta amyloid brain pathology.^1 [^18F]Flutemetamol is a PET imaging agent being developed by GE Healthcare for the detection of beta amyloid deposits in the brain. The data from the phase III studies further confirm the potential application of [^18F]flutemetamol as an imaging agent to detect beta amyloid plaques.
Market News and Data brought to you by Benzinga APIs
Posted In: NewsFDA
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...